Indrani W Gunawardana

USPTO Granted Patents = 16 (Patent Applications = 4)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 9.1

ph-index = 5

Forward Citations = 99(Granted Patents)

Location History:

Longmont, CO (US) (2011 - 2014)
Boulder, CO (US) (2012 - 2020)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2011-2020

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10766881 - 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases (2020-09-08),

2. 10208024 - 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases (2019-02-19),

3. 10154995 - Serine/threonine kinase inhibitors (2018-12-18),

4. 9969727 - Pyrrolopyridines as kinase inhibitors (2018-05-15),

5. 9763942 - Serine/threonine kinase inhibitors (2017-09-19),

6. 9670208 - Serine/threonine kinase inhibitors (2017-06-06),

7. 9365568 - Pyrrolopyridines as kinase inhibitors (2016-06-14),

8. 9079890 - Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives (2015-07-14),

9. 8981085 - Pyrrolopyridines as kinase inhibitors (2015-03-17),

10. 8853409 - Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus (2014-10-07),

11. 8841304 - Pyrrolopyridines as kinase inhibitors (2014-09-23),

12. 8758830 - Pyrrolopyridines as kinase inhibitors (2014-06-24),

13. 8372842 - Pyrazolopyridines as kinase inhibitors (2013-02-12),

14. 8212045 - Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus (2012-07-03),

15. 8178131 - Pyrrolopyridines as kinase inhibitors (2012-05-15),

Title: Indrani W Gunawardana: A Pathbreaking Innovator in FGFR Inhibitors

Introduction: Indrani W Gunawardana is an esteemed inventor based in Boulder, CO, known for his significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 16 patents, Gunawardana has been instrumental in developing innovative solutions for diseases that require targeted therapies.

Latest Patents: Among his latest innovations, Gunawardana has developed compounds that belong to the class of 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one. These compounds serve as inhibitors of fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, and FGFR4), which play a significant role in various diseases. The proposed compounds, detailed in his patent applications, highlight their potential for treating and preventing diseases mediated by FGFR signaling pathways, showcasing his commitment to advancing medical science.

Career Highlights: Gunawardana's career includes valuable experience with prominent companies in the pharmaceutical industry, such as Array Biopharma Inc. and Genentech, Inc. His expertise in drug discovery and development has positioned him as a leading inventor in his field, and his patents reflect his innovative approach to tackling complex health challenges.

Collaborations: Throughout his career, Gunawardana has collaborated with notable professionals, including James F Blake and Peter J Mohr. These partnerships have propelled his research forward and fostered an environment of creativity and scientific inquiry.

Conclusion: Indrani W Gunawardana stands out as a prolific inventor whose work on FGFR inhibitors holds promise for the treatment of various diseases. His contributions not only enhance our understanding of targeted therapies but also pave the way for future innovations in medicinal chemistry, demonstrating the vital role of inventors in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.